Clavenir 1 g

/ BioAvenir

Clavenir 1G must only be administered intravenously. The posology, by convention, is expressed in the amount of amoxicillin, depending on body weight, age and renal function of the patient, as well as the severity of the infection. The length of treatment must be as indicated and not surpass 14 days without a revision.
This dosage is not suitable for children, using in this case the 500/50 mg presentation.
Adults:
Dosage in patients with normal renal function: The usual posology is 1 g of amoxicillin, twice or four times a day by very slow, direct intravenous administration or rapid perfusion. In septicaemia and serious infections, the dose can be increased to 6 g and even up to 12 g of amoxicillin daily. Do not surpass administration of 200 mg of clavulanic acid per injection and that of 1200 mg per day in an adult. For a dose of up to 6 g daily use the “1g/200mg” presentation and for a dose of up to 12 g daily use that of “2g/200mg”.
Dosage in surgical prophylaxis: In operations lasting under 1 hour, only 1g will be administered intravenously during induction to the anaesthetic.
In longer operations further doses of 1 g may be necessary (up to a maximum of 4g in 24 hours). If the operation involves a high risk of infection, administration can continue for several days as post-operative treatment, either intravenously or orally.
Dosage in patients with renal insufficiency: See prescribing information for full details.
Dosage in hemodialysis: Initial dose of 1g/200 mg of Clavenir 1g followed by 500 mg (half vial) every 24 hours, with an additional dose of 500 mg (half vial) at the end of the dialysis.
Dosage in patients with hepatic insufficiency: Administer dosage with care, control the hepatic function at regular intervals.
The following indications must be respected, considering as inexcusable
the periods indicated:
Do not administer over 1g/200mg of Clavenir 1G intravenously (direct), or over 2g/200mg per perfusion.
See prescribing information for full details.

Clavenir 1G is indicated for short-term treatment of bacterial infections in the following areas when it is suspected that they are caused by betalactamase-producing, amoxicillin-resistant stocks. In other situations, amoxicillin alone should be considered.
Mixed infections caused by amoxicillin-sensitive germs and betalactamase-producing germs sensitive to amoxicillin / clavulanic acid can be treated with Clavenir 1G. These infections do not require an additional antibiotic stable to betalactamase action.
Infections of the upper respiratory tract (including ORL2), in particular sinusitis, otitis media and recurrent tonsillitis. These infections are often produced by Streptococcus pneumoniae, Haemophilus influenzae*, Moraxella catarrhalis* and Streptococcus pyogenes.
Infections of the lower respiratory tract, in particular acute exacerbation of chronic bronchitis (especially if considered to be serious), bronchopneumonia.
These infections are often caused by Streptococcus pneumoniae, Haemophilus influenzae* and Moraxella catarrhalis*.
Infections of the genitourinary tract and abdominal infections, in particular cystitis (especially when it is recurrent or complicated, excluding prostatitis), septic abortion, pelvic or puerperial sepsis, intra abdominal sepsis and peritonitis, which are often caused by enterobacteria* (mainly Escherichia coli*), Staphylococcus saprophyticus spp, and Enterococcus spp.
Infections of the skin and soft tissue, in particular cellulitis, animal bites and dental abscesses with disseminated cellulitis that are often caused by Sthaphylococcus aureus*, Streptococcus pyogenes and Bacteroides spp.*
Bone and joint infections
Septicaemia.
Post-operative infections: Prophylaxis against infections associated with major surgery, such as gastrointestinal, pelvic, of the head and neck, cardiac, renal, joint prosthesis, surgery of the bile ducts.
A list of sensitive germs is detailed in Pharmacological Properties.
*Some stocks of these germs produce betalactamases, which make
them insensitive to amoxicillin alone.

Clavenir 1G must not be administered to patients with a history of hypersensitivity to betalactamic antibiotics, for example, penicillin and cephalosporins, or infectious mononucleosis afflictions.
Lymphoid leukaemia.
It is contraindicated in patients with a history of jaundice or hepatic insufficiency associated with the product.